HOYNG ROKH MONEGIER is pleased to announce the expansion of its EU Regulatory Life Sciences Practice with the appointment of Dr. Alexander Meier as counsel per 1 May 2017.
Alex has in depth pharmaceutical law expertise with more than 16 years of experience as both outside counsel and inhouse lawyer. For the last eleven years Alex has worked for Novartis. Within Novartis Alex held several roles of increasing responsibility, such as Head of Legal Germany for Sandoz and Global Head, Legal of TechOps, Regulatory and Development for Novartis Pharma. Most recently Alex assumed the role of Head of Legal, Global and Pharma Drug Development of Novartis, providing EU regulatory legal support to all Global Development Functions and across the portfolio of the originator divisions (general medicines and oncology including cell & gene products).
Alex is a German trained lawyer and holds a Ph.D. in Genetic Engineering and Food Law. Alex is also lecturer at the University of Marburg (Germany) at the master degree program (LL.M.) for pharma law. Alex regularly publishes scientific articles and is co-author of the textbook “Pharmarecht” (2014).
Alex will join the Amsterdam EU Regulatory Life Sciences team which is headed by Carla Schoonderbeek. Together with Bart Jong the team enjoys a wealth of experience in assisting clients in the areas of pharmaceuticals, biologicals and medical devices. They advise and represent a large number of head offices of major pharmaceutical and biotech companies based in and outside of the EU. The team deals with regulatory issues at both European and national level concerning market authorisation and market access, regulatory exclusivity rights, orphan and paediatric medicines, pharmacovigilance, transparency, pricing, reimbursement and compliance.
The Amsterdam team works in close cooperation with the Regulatory Life Sciences teams in the other HOYNG ROKH MONEGIER offices. In the 2017 rankings of Chambers Europe HOYNG ROKH MONEGIER is ranked in band 1 in the category Europe-wide Regulatory Life Science / Pharma.